Market Access NICE’s health inequalities modular update: Commentary on NIC... NICE’s modular update on health inequalities, consulted on in January and finalised in May, has now been incorporated into its manual.1 A total of 26 individuals and organi
News Charities call for shake-up in UK rare disease R&D LifeArc and Genetics Alliance UK have issued a call to the government to remove obstacles impeding R&D into rare diseases.
News NICE relents on Takeda colorectal cancer drug Fruzaqla Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.
News NHS starts first national rollout of Blenrep for myeloma England is the first country in the world to make GSK's relaunched anti-BCMA drug Blenrep available to patients with multiple myeloma.
Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
News NICE backs new drugs for Crohn's disease, lymphoma Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face